{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T12:51:13Z","timestamp":1764852673819,"version":"3.46.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":257,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.lrr.2025.100546","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T01:00:40Z","timestamp":1758070840000},"page":"100546","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Asciminib and inotuzumab ozogamicin: a new combination for highly refractory Ph-positive B-cell acute lymphoblastic leukemia"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9700-4141","authenticated-orcid":false,"given":"Aneta","family":"Strumilowska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Devitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Conant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juli-Anne","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Volaric","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neel","family":"Hegde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Adrianzen-Herrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.lrr.2025.100546_bib0001","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s11912-012-0247-7","article-title":"Philadelphia-positive acute lymphoblastic leukemia: current treatment options","volume":"14","author":"Liu-Dumlao","year":"2012","journal-title":"Curr. Oncol. Rep."},{"issue":"3","key":"10.1016\/j.lrr.2025.100546_bib0002","first-page":"216","article-title":"Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: current treatments and future perspectives","volume":"16","author":"Yilmaz","year":"2018","journal-title":"Clin. Adv. Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.lrr.2025.100546_bib0003","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1182\/bloodadvances.2023012162","article-title":"Tyrosine kinase inhibitor resistance in de novo BCR::ABL1\u2013positive BCP-ALL beyond kinase domain mutations","volume":"8","author":"van Outersterp","year":"2024","journal-title":"Blood Adv."},{"issue":"7","key":"10.1016\/j.lrr.2025.100546_bib0004","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/cncr.28522","volume":"120","author":"Soverini","year":"2014","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.lrr.2025.100546_bib0005","first-page":"196","article-title":"Philadelphia positive acute lymphoblastic leukemia in adults: age distribution, BCR breakpoint and prognostic significance","volume":"5","author":"Secker-Walker","year":"1991","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.lrr.2025.100546_bib0006","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol."},{"issue":"1","key":"10.1016\/j.lrr.2025.100546_bib0007","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41408-023-00848-0","article-title":"CD19 chimeric antigen receptor T-cell therapy in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia without complete molecular response at 3 months","volume":"13","author":"Yao","year":"2023","journal-title":"Blood Cancer J."},{"issue":"5","key":"10.1016\/j.lrr.2025.100546_bib0008","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.V97.5.1211","article-title":"Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01","volume":"97","author":"Silverman","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.lrr.2025.100546_bib0009","article-title":"Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia","author":"Luskin","year":"2024","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.lrr.2025.100546_bib0010","doi-asserted-by":"crossref","first-page":"261","DOI":"10.14740\/jmc4287","article-title":"Combination Therapy With Asciminib and Ponatinib as a Bridge to Brexucabtagene Autoleucel and Maintenance in a Patient With Relapsed Refractory Philadelphia Positive B-Cell Acute Lymphoblastic Leukemia","volume":"15","author":"Amin Muhammad","year":"2024","journal-title":"J. Med. Cases."},{"issue":"14","key":"10.1016\/j.lrr.2025.100546_bib0011","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1080\/10428194.2021.1966787","article-title":"Asciminib and ponatinib combination in Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"62","author":"Zerbit","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.lrr.2025.100546_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2023.107299","article-title":"Ponatinib, asciminib and inotuzumab ozogamicin: a novel drug combination in acute lymphoblastic leukemia","volume":"129","author":"Tinajero","year":"2023","journal-title":"Leuk. Res."},{"issue":"1","key":"10.1016\/j.lrr.2025.100546_bib0013","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1186\/s12885-020-06782-9","article-title":"The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib","volume":"20","author":"HJ","year":"2020","journal-title":"BMC. Cancer"},{"issue":"4","key":"10.1016\/j.lrr.2025.100546_bib0014","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ccell.2019.08.004","article-title":"Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants","volume":"36","author":"Eide","year":"2019","journal-title":"Cancer Cell"},{"year":"2024","series-title":"Asciminib For Relapsed Or Refractory Philadelphia Postive Acute Lymphoblastic Leukemia (PH+ ALL) and Lymphoid Blast Crisis Chronic Myelogenous Leukemia","author":"Mathilde CHANUT","key":"10.1016\/j.lrr.2025.100546_bib0015"},{"issue":"3","key":"10.1016\/j.lrr.2025.100546_bib0016","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.23.00546","article-title":"Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL","volume":"42","author":"Stelljes","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.lrr.2025.100546_bib0017","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.3324\/haematol.2021.280433","article-title":"Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and BCR-ABL-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin","volume":"107","author":"Kayser","year":"2022","journal-title":"Haematologica"}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048925000482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048925000482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T12:47:14Z","timestamp":1764852434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048925000482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":17,"alternative-id":["S2213048925000482"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2025.100546","relation":{},"ISSN":["2213-0489"],"issn-type":[{"type":"print","value":"2213-0489"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Asciminib and inotuzumab ozogamicin: a new combination for highly refractory Ph-positive B-cell acute lymphoblastic leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2025.100546","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100546"}}